Position in HLN
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$3,197,707
+$1,219,522 QoQ
Shares Held
342,734
+73.4% QoQ
Ownership
0.008%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#89
of 639 holders
Holding Since
Sep 2024
8 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in HLN Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Jun 30, 2026AQR CAPITAL MANAGEMENT LLC holds $1,405,033,456 across 42 Drug Manufacturers - Specialty & Generic names. HLN ranks #29 (0.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | NBIX |
Neurocrine Biosciences Inc
|
3,818,037 | $643,491,951 | |
| 2 | UTHR |
UNITED THERAPEUTICS Corp
|
546,002 | $295,840,259 | |
| 3 | ZTS |
Zoetis Inc.
|
1,070,929 | $76,956,955 | |
| 4 | VTRS |
Viatris Inc
|
4,694,966 | $74,556,056 | |
| 5 | PRGO |
PERRIGO Co plc
|
3,480,666 | $36,164,117 | |
| 6 | LNTH |
Lantheus Holdings, Inc.
|
261,250 | $28,983,071 | |
| 7 | IRWD |
Ironwood Pharmaceuticals Inc
|
6,465,921 | $27,221,524 | |
| 8 | TAK |
Takeda Pharmaceutical Co Ltd
|
1,525,686 | $24,456,745 |
All Filings in HLN
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $3,197,707 | 342,734 | Shares | Other | 2026-08-14 | |
| 2026-03-31 | $1,978,185 | 197,621 | Shares | Defined | 2026-05-15 | |
| 2025-12-31 | $1,515,033 | 149,855 | Shares | Defined | 2026-02-17 | |
| 2025-09-30 | $1,244,622 | 138,754 | Shares | Defined | 2025-11-14 | |
| 2025-06-30 | $1,328,438 | 128,104 | Shares | Other | 2025-08-14 | |
| 2025-03-31 | $991,162 | 96,323 | Shares | Other | 2025-05-15 | |
| 2024-12-31 | $749,871 | 78,603 | Shares | Other | 2025-02-14 | |
| 2024-09-30 | $706,955 | 66,820 | Shares | Defined | 2024-11-14 | |
| No filing history on record for this holder in this stock. | ||||||